Heron Therapeutics Statistics
Total Valuation
HRTX has a market cap or net worth of $160.53 million. The enterprise value is $257.38 million.
Important Dates
The last earnings date was Monday, May 11, 2026, before market open.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HRTX has 189.28 million shares outstanding. The number of shares has increased by 14.85% in one year.
| Current Share Class | 189.28M |
| Shares Outstanding | 189.28M |
| Shares Change (YoY) | +14.85% |
| Shares Change (QoQ) | +0.86% |
| Owned by Insiders (%) | 0.83% |
| Owned by Institutions (%) | 55.69% |
| Float | 135.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.07 |
| Forward PS | 1.15 |
| PB Ratio | 19.78 |
| P/TBV Ratio | 19.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.53, with a Debt / Equity ratio of 15.50.
| Current Ratio | 2.53 |
| Quick Ratio | 1.42 |
| Debt / Equity | 15.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.88 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -2.71% |
| Return on Invested Capital (ROIC) | -4.36% |
| Return on Capital Employed (ROCE) | -6.72% |
| Weighted Average Cost of Capital (WACC) | 10.36% |
| Revenue Per Employee | $1.18M |
| Profits Per Employee | -$241,727 |
| Employee Count | 128 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 0.75 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.95% in the last 52 weeks. The beta is 1.71, so HRTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.71 |
| 52-Week Price Change | -56.95% |
| 50-Day Moving Average | 0.96 |
| 200-Day Moving Average | 1.20 |
| Relative Strength Index (RSI) | 35.33 |
| Average Volume (20 Days) | 2,644,341 |
Short Selling Information
The latest short interest is 40.88 million, so 21.60% of the outstanding shares have been sold short.
| Short Interest | 40.88M |
| Short Previous Month | 41.15M |
| Short % of Shares Out | 21.60% |
| Short % of Float | 30.14% |
| Short Ratio (days to cover) | 21.43 |
Income Statement
In the last 12 months, HRTX had revenue of $150.71 million and -$30.94 million in losses. Loss per share was -$0.18.
| Revenue | 150.71M |
| Gross Profit | 94.65M |
| Operating Income | -10.46M |
| Pretax Income | -30.94M |
| Net Income | -30.94M |
| EBITDA | -8.17M |
| EBIT | -10.46M |
| Loss Per Share | -$0.18 |
Full Income StatementBalance Sheet
The company has $44.78 million in cash and $141.63 million in debt, with a net cash position of -$96.85 million or -$0.51 per share.
| Cash & Cash Equivalents | 44.78M |
| Total Debt | 141.63M |
| Net Cash | -96.85M |
| Net Cash Per Share | -$0.51 |
| Equity (Book Value) | 9.14M |
| Book Value Per Share | 0.04 |
| Working Capital | 138.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$20.26 million and capital expenditures -$599,000, giving a free cash flow of -$20.86 million.
| Operating Cash Flow | -20.26M |
| Capital Expenditures | -599,000 |
| Depreciation & Amortization | 2.29M |
| Net Borrowing | -12.76M |
| Free Cash Flow | -20.86M |
| FCF Per Share | -$0.11 |
Full Cash Flow StatementMargins
Gross margin is 62.80%, with operating and profit margins of -6.94% and -20.53%.
| Gross Margin | 62.80% |
| Operating Margin | -6.94% |
| Pretax Margin | -20.53% |
| Profit Margin | -20.53% |
| EBITDA Margin | -5.42% |
| EBIT Margin | -6.94% |
| FCF Margin | n/a |
Dividends & Yields
HRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.85% |
| Shareholder Yield | -14.85% |
| Earnings Yield | -19.27% |
| FCF Yield | -12.99% |
Analyst Forecast
The average price target for HRTX is $3.67, which is 332.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.67 |
| Price Target Difference | 332.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 16.70% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 13, 2014. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 13, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
HRTX has an Altman Z-Score of -9.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.29 |
| Piotroski F-Score | 3 |
